OSLO, Norway, Jan. 19, 2022 /PRNewswire/ NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
/PRNewswire/ Nordic Nanovector ASA (OSE: NANOV), a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the.
Nordic Nanovector - Private placement successfully completed
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN
OSLO, Norway, Feb. 23, 2021 /PRNewswire/ Reference is made to the stock exchange release from Nordic Nanovector ASA (OSE: NANO) (
Nordic Nanovector or the
Company ), a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics, published on 23 February 2021 regarding the contemplated private placement of new shares in the Company.